Nutrition 21
This article was originally published in The Tan Sheet
Executive Summary
Firm's total revenues for the first fiscal quarter of 2006 (ended Sept. 30) increased 31% to $3.6 mil., Purchase, N.Y.-company announces Nov. 1. The chromium picolinate marketer also saw gross profit increase to $3 mil., 41% higher than gross profit in the first quarter of 2005. An August announcement by FDA that chromium picolinate is safe for use in those with type 2 diabetes "should help contribute to increased sales and improved gross margins as we move forward," Nutrition 21 maintains. Separately, the firm's CEO Gail Montgomery resigned Nov. 4. She had held her posts as President, CEO and a director since September 2000. CFO Paul Intlekofer has been named COO and will be considered a candidate for the CEO post as well, the firm adds...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.